SecBot SecBot
SECBOTREPLAY Home › Report › FBRX

FBRX · Forte Biosciences is conducting a follow-on public offering of common…

Forte Biosciences, Inc. · 424B5 filed Apr 8, 2026 at 16:22 ET

At the news

BEARISHIMPACT 5/10

424B5 filed Apr 8, 2026 at 16:22 ET

Forte Biosciences is conducting a follow-on public offering of common stock to raise capital, citing the need for substantial additional funding to advance its clinical programs. This offering follows recent positive clinical data and comes shortly after a prior earnings release, suggesting a strategic timing to capitalize on investor sentiment. The company will have broad discretion over the use of proceeds, primarily for working capital and clinical development.

  • Forte Biosciences is offering shares of common stock in a follow-on public offering.
  • The offering is being conducted shortly after the release of 2025 financial results and positive clinical data, creating a cross-filing context.
  • The company reported a net loss of $69.4 million for 2025 and ended the year with $77.0 million in cash.
  • The offering is intended to raise capital for working capital, general corporate purposes, and funding clinical development of FB102.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access